close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Editas Medicine, Inc.

< Previous 1 2 Next >
News headline image
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces First Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers BMY EDIT
News headline image
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Pricing of Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today